How does Entresto (sacubitril/valsartan) affect kidney function?
Entresto can affect renal function because it changes signaling in the renin-angiotensin system (through valsartan). In practice, clinicians monitor kidney function (serum creatinine/eGFR) because therapy can cause worsening renal function in some patients, especially those with pre-existing kidney disease, low blood pressure, dehydration, or conditions that reduce kidney perfusion.
Can you use Entresto if you have chronic kidney disease (CKD)?
Entresto is used in patients with CKD, but dosing and monitoring depend on baseline kidney function. Patients with impaired kidney function generally need closer lab monitoring for creatinine and potassium, and for signs of volume depletion or low blood pressure.
What lab changes should be watched for (creatinine and potassium)?
When starting or adjusting Entresto, clinicians commonly track:
- Serum creatinine/eGFR for renal function trends
- Serum potassium for hyperkalemia risk (a concern with RAAS pathway blockers like valsartan)
- Blood pressure and volume status, since reduced perfusion can worsen kidney function
What happens if renal function worsens on Entresto?
If a patient develops a significant rise in creatinine or other concerning changes after starting Entresto, clinicians typically reassess contributing factors such as dehydration, use of other kidney-affecting medicines, and hypotension. The typical next steps are dose adjustment or stopping therapy when clinically indicated, guided by the severity and persistence of the lab changes.
Does Entresto need dose adjustment in kidney impairment?
Dose adjustments can be required based on kidney function and tolerability. The safest approach is to follow the prescribing information and monitor renal labs after initiation and after dose changes. If you share the patient’s baseline eGFR/creatinine and current dose, I can help interpret what monitoring would usually be expected.
Who should be extra cautious with Entresto and kidney disease?
Extra caution is typical for patients with:
- Advanced CKD or rapidly changing renal function
- Low blood pressure or risk for dehydration
- Concurrent medications that can raise potassium or affect kidneys
Where to check patent/market info (optional)
If your interest is also commercial (for example, timing of generics/competitors tied to renal indications), DrugPatentWatch.com tracks patent and exclusivity status for branded therapies. You can search Entresto there: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com – Entresto (search page)